RADTHYR: an open-label, single-arm, prospective multicenter phase II trial of Radium-223 for the treatment of bone metastases from radioactive iodine refractory differentiated thyroid cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1619-7089
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
RADTHYR: an open-label, single-arm, prospective multicenter phase II trial of Radium-223 for the treatment of bone metastases from radioactive iodine refractory differentiated thyroid cancer ; day:23 ; month:2 ; year:2021 ; pages:1-12
European journal of nuclear medicine and molecular imaging ; (23.2.2021), 1-12
- Creator
-
Deandreis, Désirée
Maillard, Aline
Zerdoud, Slimane
Bournaud, Claire
Vija, Lavinia
Sajous, Christophe
Terroir, Marie
Leenhardt, Laurence
Schlumberger, Martin
Borget, Isabelle
Leboulleux, Sophie
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00259-021-05229-y
- URN
-
urn:nbn:de:101:1-2021041113030256097198
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:49 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Deandreis, Désirée
- Maillard, Aline
- Zerdoud, Slimane
- Bournaud, Claire
- Vija, Lavinia
- Sajous, Christophe
- Terroir, Marie
- Leenhardt, Laurence
- Schlumberger, Martin
- Borget, Isabelle
- Leboulleux, Sophie
- SpringerLink (Online service)
Other Objects (12)
Predictive Factors of Radioactive Iodine Therapy Refractoriness in Patients with Differentiated Thyroid Carcinoma
Causes of False-Positive Radioactive Iodine Uptake in Patients with Differentiated Thyroid Cancer
Risk and outcome of subsequent malignancies after radioactive iodine treatment in differentiated thyroid cancer patients
Myxedema Psychosis after Levothyroxine Withdrawal in Radioactive Iodine Treatment of Differentiated Thyroid Cancer: A Case Report
Bone metastases from differentiated thyroid carcinoma: heterogenous tumor response to radioactive Iodine therapy and overall survival
How Radioactive Iodine Treatment Affects the Retina
Can 18F-fluorodeoxyglucose positron emission tomography predict the response to radioactive iodine therapy in metastatic differentiated thyroid carcinoma?
Radioactive Body Burden Measurements in 131 Iodine Therapy for Differentiated Thyroid Cancer: Effect of Recombinant Thyroid Stimulating Hormone in Whole Body 131 Iodine Clearance
68Ga-PSMA PET/CT in radioactive iodine-refractory differentiated thyroid cancer and first treatment results with 177Lu-PSMA-617
Graves’ Disease-Related Pancytopenia Improved after Radioactive Iodine Ablation
Second primary malignancies induced by radioactive iodine treatment of differentiated thyroid carcinoma — a critical review and evaluation of the existing evidence
Levothyroxine-induced serum free thyroxine response following radioactive iodine administration in patients thyroidectomized for differentiated thyroid cancer: A randomized controlled trial
Predictive Factors of Radioactive Iodine Therapy Refractoriness in Patients with Differentiated Thyroid Carcinoma
Causes of False-Positive Radioactive Iodine Uptake in Patients with Differentiated Thyroid Cancer
Risk and outcome of subsequent malignancies after radioactive iodine treatment in differentiated thyroid cancer patients
Myxedema Psychosis after Levothyroxine Withdrawal in Radioactive Iodine Treatment of Differentiated Thyroid Cancer: A Case Report
Bone metastases from differentiated thyroid carcinoma: heterogenous tumor response to radioactive Iodine therapy and overall survival
How Radioactive Iodine Treatment Affects the Retina
Can 18F-fluorodeoxyglucose positron emission tomography predict the response to radioactive iodine therapy in metastatic differentiated thyroid carcinoma?
Radioactive Body Burden Measurements in 131 Iodine Therapy for Differentiated Thyroid Cancer: Effect of Recombinant Thyroid Stimulating Hormone in Whole Body 131 Iodine Clearance
68Ga-PSMA PET/CT in radioactive iodine-refractory differentiated thyroid cancer and first treatment results with 177Lu-PSMA-617
Graves’ Disease-Related Pancytopenia Improved after Radioactive Iodine Ablation
Second primary malignancies induced by radioactive iodine treatment of differentiated thyroid carcinoma — a critical review and evaluation of the existing evidence
Levothyroxine-induced serum free thyroxine response following radioactive iodine administration in patients thyroidectomized for differentiated thyroid cancer: A randomized controlled trial
Predictive Factors of Radioactive Iodine Therapy Refractoriness in Patients with Differentiated Thyroid Carcinoma
Causes of False-Positive Radioactive Iodine Uptake in Patients with Differentiated Thyroid Cancer
Risk and outcome of subsequent malignancies after radioactive iodine treatment in differentiated thyroid cancer patients
Myxedema Psychosis after Levothyroxine Withdrawal in Radioactive Iodine Treatment of Differentiated Thyroid Cancer: A Case Report
Bone metastases from differentiated thyroid carcinoma: heterogenous tumor response to radioactive Iodine therapy and overall survival
How Radioactive Iodine Treatment Affects the Retina
Can 18F-fluorodeoxyglucose positron emission tomography predict the response to radioactive iodine therapy in metastatic differentiated thyroid carcinoma?
Radioactive Body Burden Measurements in 131 Iodine Therapy for Differentiated Thyroid Cancer: Effect of Recombinant Thyroid Stimulating Hormone in Whole Body 131 Iodine Clearance
68Ga-PSMA PET/CT in radioactive iodine-refractory differentiated thyroid cancer and first treatment results with 177Lu-PSMA-617
Graves’ Disease-Related Pancytopenia Improved after Radioactive Iodine Ablation
Second primary malignancies induced by radioactive iodine treatment of differentiated thyroid carcinoma — a critical review and evaluation of the existing evidence